Novo Nordisk shares plunge 22% after CagriSema obesity drug trial results
Shares of Danish pharmaceutical giant Novo Nordisk plummeted more than 22% on Friday after reporting results in a late-stage trial that missed expectations.
Novo Nordisk's next-gen obesity drug CagriSema achieves lower weight loss than expected
Novo Nordisk said on Friday its experimental next-generation obesity drug CagriSema helped overweight patients cut their weight by 22.7% in a late-stage trial, below the 25% it had expected, sending its shares down sharply.
Novo Nordisk's Ozempic faces EU review for potential eye disease connection
The European Union's drug regulator said it would assess two new Danish studies that link Novo Nordisk's popular diabetes drug Ozempic to a rare eye disease.
Healthy Returns: Novo Nordisk's Ozempic faces scrutiny over potential link to rare eye condition
A vision-threatening eye condition may be linked to Ozempic. Meanwhile, Nearly 80% of doctors are using telemedicine weekly, a new Doximity report finds.
NVO to Invest $1.2B in New Rare Disease Drugs Facility in Denmark
Novo Nordisk is set to invest $1.2 billion for a new facility in Odense, Denmark, to produce various product types for rare diseases, including haemophilia.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Novo's Ozempic faces scrutiny over potential link to rare eye disease
Danish health authorities said on Monday they would ask the European Union's drug regulator to review the findings of two Danish studies linking Novo Nordisk's popular diabetes drug Ozempic to a rare sight-threatening eye condition.
Novo Nordisk plans $1.2bn Danish factory investment
Novo Nordisk (NYSE:NVO), the Danish pharmaceutical company, plans to invest $1.2 billion in a new production facility in Odense, Denmark, focused on treatments for rare diseases. In an announcement, the company said the site will feature both a factory and a warehouse, designed to be modular and adaptable to support various rare disease products, including treatments for haemophilia.
Novo Nordisk to invest $1.2 bln in new plant in Denmark
Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense, Denmark, for the production of rare disease drugs, it said on Monday.
Novo Nordisk's Ozempic Potentially Linked To Rare Vision Loss Risk, But Absolute Risk Is Low: Study
A recent cohort study conducted in Denmark and Norway reveals a potential link between the use of semaglutide for type 2 diabetes and an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION).
NVO Gets Positive CHMP Opinion in EU for Ozempic Expanded Use in CKD
Novo Nordisk's diabetes drug, Ozempic, receives positive CHMP opinion in the EU for expanded use in T2D and CKD patients.
Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling.
Novo Nordisk's Ozempic will become the first and only GLP-1 drug to be shown to reduce progression of kidney disease in adults with Type 2 diabetes.
